Autres langues Tenax Therapeutics, Inc.

Actions

TENX

US88032L6056

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:11:55 05/10/2026			Varia. 5j.	Varia. 1 janv.
1,925 ^USD	-2,78%		+4,32%	-84,17%

31/08	Tenax Therapeutics, Inc. : Guggenheim moins optimiste	ZM
29/08	Tenax Therapeutics présente des résultats complémentaires de l'essai clinique de phase 3 évaluant le TNX-103 chez des patients atteints d'hypertension pulmonaire due à une insuffisance cardiaque à fraction d'éjection préservée	CI

Autres langues

21/09	Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to S&P Global BMI Index
01/09	Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
29/08	Tenax Therapeutics Presents Additional Results from Phase 3 Level Clinical Trial Evaluating Tnx-103 in Patients with Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction
29/08	Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
10/08	Tenax Therapeutics Announces Topline Results from Phase 3 Level Clinical Trial of Tnx-103 in Patients with Ph-Hfpef
10/08	Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial
10/08	Tenax Therapeutics Says Late-Stage Trial Misses Primary, Secondary Endpoints
10/08	Tenax's TNX-103 Misses Primary Endpoint in Phase 3 Pulmonary Hypertension Trial
10/08	Top Premarket Decliners
10/08	Tenax heart drug fails to improve walking results in study, shares plunge
10/08	Tenax Therapeutics' heart drug misses main goal in late-stage study
10/08	Orion Reports Phase 3 LEVEL Trial Results For Oral Levosimendan In Pulmonary Hypertension Due To Heart Failure With Preserved Ejection Fraction
10/08	Tenax Therapeutics Reports Phase 3 LEVEL Trial Results For Oral Levosimendan In PH-HFpEF
10/08	Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
31/07	Tenax Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
31/07	Tenax Therapeutics: Q2 Earnings Snapshot
31/07	Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
02/07	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07	Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June
02/07	Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
29/06	Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell 2000 Index
29/06	Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell 2000 Value Benchmark
29/06	Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell Microcap Value Benchmark Index
29/06	Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell 3000E Index
29/06	Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell 3000E Value Benchmark